Vor Biopharma (VOR) Net Income towards Common Stockholders (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$31.3 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 3.54% year-over-year to -$31.3 million in Q1 2026; TTM through Mar 2026 was -$2.5 billion, a 1937.7% decrease from a year earlier, with the FY2025 full-year figure at -$598.5 million, down 133.68% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$31.3 million, up from -$33.3 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for VOR reached as high as -$21.7 million in Q2 2022 and fell as low as -$1.6 billion in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$165.4 million across 5 years, with a median of -$30.0 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders climbed 16.97% in 2024 and plunged 5552.75% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$23.9 million in 2022, then slipped by 9.83% to -$26.3 million in 2023, then declined by 23.37% to -$32.4 million in 2024, then dropped by 2.71% to -$33.3 million in 2025, then gained by 5.83% to -$31.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$31.3 million in Q1 2026, -$33.3 million in Q4 2025, and -$812.7 million in Q3 2025.